Exclusive: Kevin Weil says Warp's early customers are interested in moving drug-discovery work back to the U.S.
The former OpenAI executive's new lab startup told RuntimeWire it wants to "partner broadly with the frontier labs." Its own site lists OpenAI and Anthropic leaders among its angels.
By Morgan Laning · Published
Why it matters
Weil says Warp's early customers are interested in moving drug-discovery work back to the U.S. for commercial, intellectual-property and geopolitical reasons.

The former OpenAI executive's new lab startup told RuntimeWire it wants to "partner broadly with the frontier labs." Its own site lists OpenAI and Anthropic leaders among its angels.
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.